Kristina Jenei, Associate Editor at the Journal of Cancer Policy, recently posted on X:
“I watched IQVIA trends for the next year so you don’t have to.
– Generic rx increasing,
– Innovative launches struggling (down 28%),
– Global market rising driven by biologics, thanks pembrolizumab! Small molecules CD4KIs, GLP1s, etc..
A couple more things: ONCOLOGY, ONCOLOGY, ONCOLOGY.”
Source: Kristina Jenei/X